Navigation Links
Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
Date:4/10/2013

CAMBRIDGE, Mass., April 10, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel bispecific therapy MM-111 restored tumor sensitivity to the chemotherapy agent, paclitaxel, and HER2-targeted treatment, trastuzumab, in a HER2+ gastric cancer model. The research was presented as part of the American Association for Cancer Research's 2013 Annual Meeting in Washington, DC, April 6-10, 2013.

Overexpression of the HER2 (ErbB2) cell surface receptor has been reported in 10-25 percent of gastric and esophageal cancers. The HER2 receptor triggers tumor growth and survival when it binds together with an additional receptor known as HER3 (ErbB3) and another protein called heregulin. HER3 expression has been associated with poor prognosis in gastric cancer. MM-111 is designed to anchor to both receptors, HER2 and HER3, on the cell surface and block heregulin's ability to transmit tumor growth signals, thus inhibiting the tumor cell's ability to thrive.

"The protein heregulin can often cause resistance to standard chemotherapy and targeted treatments in gastric tumors that express both HER2 and HER3," said Ulrik Nielsen , PhD, Co-Founder and Chief Scientific Officer of Merrimack. "We are encouraged to see that this resistance is overcome in preclinical models when MM-111 is used in combination with trastuzumab and paclitaxel."

Merrimack is initiating a Phase 2 study testing MM-111 in combination with paclitaxel or with paclitaxel and trastuzumab for the treatment of advanced gastric, esophageal and gastroesophageal junction (GEJ) cancers.  Merrimack is also currently conducting a Phase 1 study of MM-111 across multiple HER2+ tumors, including breast, colorectal, gas
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Merrimack Pharmaceuticals Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
2. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
3. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
4. Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant to Further Develop Mass Vaccination Device
5. Faruqi & Faruqi, LLP is Investigating Peregrine Pharmaceuticals Inc. on Behalf of its Shareholders - PPHM
6. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
7. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
8. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
9. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Regeneron Pharmaceuticals Announces Expansion in New Yorks Hudson Valley
11. Valeant Pharmaceuticals Provides Update to Recent Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  Boston Children,s Hospital physicians report ... printing of their anatomy before undergoing high-risk brain ... (abnormalities in the brain,s blood vessels) that posed ... in the Journal of Neurosurgery: Pediatrics , ... and synthetic resins to create custom, high-fidelity models ...
(Date:7/31/2015)...  Semler Scientific, Inc. (Nasdaq: SMLR ), a ... insurers and physician groups, today reported financial results for ... "In the second quarter of 2015, Semler reported ... 54%, quarter over quarter revenue growth of 8%, and ... FloChec® units of 18%," said Doug Murphy-Chutorian, M.D., chief ...
(Date:7/30/2015)... Edwards Lifesciences Corporation (NYSE: EW ), the ... monitoring, today announced that Robert A. Ingram has ... is an ardent champion for innovation in the lifesciences industry, ... on Edwards, board as we pursue our focused innovation strategy," ... "Bob has provided a valuable perspective to our board, drawing ...
Breaking Medicine Technology:3D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
... Results in Patients With Follicular Lymphoma Reported,Today ... 2007 /PRNewswire/ -- GlaxoSmithKline plc,announced today long-term ... of a,single one-week course of frontline treatment ... I-131 Tositumomab) in,76 patients with newly diagnosed ...
... PARIS--(BUSINESS WIRE)--Jun 4, 2007 - Hemispherx Biopharma, ... the clinical,development of new drug entities for ... a new scientific report on the,activity of ... anti-influenza agents against highly pathogenic avian,influenza (HPAI), ...
Cached Medicine Technology:8-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7Hemispherx Presents Evidence of Ampligen Synergies with Existing,Antivirals at International Avian Influenza Conference 2Hemispherx Presents Evidence of Ampligen Synergies with Existing,Antivirals at International Avian Influenza Conference 3
(Date:7/31/2015)... ... July 31, 2015 , ... Like nearly every other form of surgery, it ... made more effective and less intrusive and painful. Leading these advances in the ... Dr. Loria currently stands as the only doctor in the United States who is ...
(Date:7/31/2015)... ... , ... The alarm was ringing. Hugh Chatfield, survivor of a severe 1987 brain injury, almost ... his equipment was set up to depict the newly poured concrete. With a clear view ... photo speaks for itself. Chatfield is also a highly praised safety and drug education speaker/comedian. ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... in Birmingham. The U.S. Women's National Soccer Team will face the Australia Women's National ... Thursday, September 17th at Ford Field in Detroit and the second match will occur ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reputable source of authentic ... Soccer Team will face the Australia Women's National Team in conjunction with their Victory Tour ... 5-2. Carli Lloyd from the USA team was awarded the Golden Ball as the ...
(Date:7/31/2015)... ... 2015 , ... ZH Healthcare announces a new cloud based service delivering Health ... as a Service (HITaaS) is a Healthcare dedicated cloud based service that sits over ... HITaaS manages all aspects of infrastructure, security, runtime, middleware, OS, virtualization, Servers, storage, ...
Breaking Medicine News(10 mins):Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4
... News) -- Many seniors may be at increased risk for ... treat thyroid problems, a new study says. The findings ... elderly patients with thyroid problems and that regular dose monitoring ... said. Reporting in the online April 28 edition of ...
... THURSDAY, April 28 (HealthDay News) -- Rising rates of ... cause for concern because excess weight is associated with ... In people with arthritis, obesity is associated with ... total joint replacement and poor outcomes after joint replacement. ...
... THURSDAY, April 28 (HealthDay News) -- Memory in monkeys and ... says. Experiments with rhesus monkeys showed that, like people, ... ability to identify something when you see it. Recall is ... study appears online April 28 in the journal Current ...
... News) -- Your social status affects how your brain ... the new study, brain activity in volunteers was measured ... increased brain activity when shown information about others at ... had greater response to others like them, the investigators ...
... which combines interval training and healthy eating practices seems ... according to the results of a new study from ... physical activity (PIC Centre). Results of the study were ... in Montreal. Within the framework of this study, ...
... oncologist practiced were two factors that strongly influenced the choice ... to an article published April 29 online in the ... IMRT and the cost of radiation therapy increased sharply over ... delivery technique that modulates the radiation beams to conform to ...
Cached Medicine News:Health News:Thyroid Drugs May Raise Fracture Risk in Elderly 2Health News:Rising Obesity Rates Add to Arthritis Woes in U.S. 2Health News:Shared Social Status Boosts Brain Activity, Research Shows 2Health News:Obesity: Conclusive results for the Montreal Heart Institute's EPIC Centre Kilo-Actif program 2Health News:Use of costly breast cancer therapy strongly influenced by reimbursement policy 2
Hartman Mosquito forceps, straight, 3.5"....
Curved 20 mm serrated jaws. Ring handle with ratchet lock and dull finish. Most popular size or model. Overall length 3.9 inches...
Shafts angled 45 degrees with 10 mm jaws. Serrated handle with polished finish. Crisscross serrated jaws. Most popular size or model....
Straight shafts with 16 mm long platform. Lengthwise serrated jaws with cross serrated tips. Serrated handle with polished finish. Platform: 2.4 mm wide....
Medicine Products: